Molly Rachel Fensterwald

Molly Fensterwald practices at Peter Morton UCLA Medical Building in Los Angeles, California.

Molly Fensterwald's NPI, 1972041671, was assigned on February 2, 2017. Molly Fensterwald graduated from UC Davis School of Medicine in 2019. Molly Fensterwald holds California license A181894.

Molly Fensterwald's primary practice is Peter Morton UCLA Medical Building, at 200 Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 794-9206.

Molly Fensterwald's primary practice is Peter Morton UCLA Medical Building in Los Angeles, California. Molly Fensterwald is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Neurology. Dmand AI also links Molly Fensterwald to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Molly Fensterwald practices, 2 sites in all. Vendor and product names are available with a free account.

Neurology is Molly Fensterwald's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Molly Fensterwald is board certified in neurology by the American Board of Psychiatry and Neurology. Molly Fensterwald is licensed in California.

Dmand AI lists migraine and chronic headache among the conditions Molly Fensterwald treats.

CMS data shows 5,929 Medicare services from Molly Fensterwald across 4 procedure codes in 2024, for 57 Medicare patients. Medicare paid $40,701 for them. Every service was in an office.

CMS counts 57 Medicare patients who saw Molly Fensterwald in 2024. The largest group is 65 to 74, with 24 patients. 74% of them have high cholesterol, and 68% have arthritis. 44% are also on Medicaid. Their average risk score is 2.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Molly Fensterwald's median patient age at 44, with 78% women.

In 2024, Molly Fensterwald wrote 380 Medicare Part D claims for 61 patients. 71% of them were for generic drugs. CMS names the drug for 279 of them, across 15 drugs with 11 or more claims each, at $140,380 in total drug cost. In 2023, CMS named 30 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Molly Fensterwald for performance year 2024, reported as part of a group. Molly Fensterwald accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Molly Fensterwald as offering telehealth.

Dmand AI links 2 papers to Molly Fensterwald in 2018. Molly Fensterwald's most frequent co-authors are Michael J. Campbell, MD, Mutaal Mahmood Akhter, MD and Naseem Eisa.

CMS Open Payments shows 7 general payments to Molly Fensterwald from 4 drug and device companies from 2023 to 2025. Food and beverage make up the largest share, 100% of the total. Pfizer Inc. paid the most, $234.

Molly Fensterwald graduated from UC Davis School of Medicine in 2019.

Molly Fensterwald is in network with 11 carriers, including United Healthcare, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.